as 11-21-2024 4:00pm EST
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | WARMINSTER |
Market Cap: | 725.9M | IPO Year: | N/A |
Target Price: | $5.50 | AVG Volume (30 days): | 837.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.43 | EPS Growth: | N/A |
52 Week Low/High: | $1.79 - $4.72 | Next Earning Date: | 11-06-2024 |
Revenue: | $6,742,000 | Revenue Growth: | -69.69% |
Revenue Growth (this year): | -64.38% | Revenue Growth (next year): | -13.12% |
ABUS Breaking Stock News: Dive into ABUS Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
GlobeNewswire
6 days ago
GlobeNewswire
6 days ago
GlobeNewswire
7 days ago
GuruFocus.com
15 days ago
Thomson Reuters StreetEvents
15 days ago
Zacks
15 days ago
Associated Press Finance
15 days ago
The information presented on this page, "ABUS Arbutus Biopharma Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.